Leiomyosarcoma epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 8: Line 8:
[[Leiomyosarcoma]] is a rare tumor subtype, accounts for 1% of all uterine malignancies, but contributes to a significant proportion of uterine cancer deaths. The incidence of uterine LMS is 0.36 per 100,000 woman-years [5]; most occur in women over 40 years of age, with incidence increasing rapidly after age 50 [9]. Black women have a 2-fold higher incidence than white women. LMS may be associated with obesity and diabetes [6]. Tamoxifen use for N5 years may also increase LMS risk to 17 per 100,000 woman-years [7]. Additionally, studies in soft tissue sarcoma have attributed an increased risk of LMS with p53 gene mutations, radiation treatment for childhood cancers, and germ line mutations in fumarate hydratase (hereditary leiomyomatosis with renal cell carcinoma) [4]. Most uterine LMS is unassociated with preexisting leiomyomas and no biologic evidence exists to link LMS with their benign, smooth muscle uterine tumors. <ref name="ToroTravis2006">{{cite journal|last1=Toro|first1=Jorge R.|last2=Travis|first2=Lois B.|last3=Wu|first3=Hongyu Julian|last4=Zhu|first4=Kangmin|last5=Fletcher|first5=Christopher D.M.|last6=Devesa|first6=Susan S.|title=Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases|journal=International Journal of Cancer|volume=119|issue=12|year=2006|pages=2922–2930|issn=00207136|doi=10.1002/ijc.22239}}</ref>
[[Leiomyosarcoma]] is a rare tumor subtype, accounts for 1% of all uterine malignancies, but contributes to a significant proportion of uterine cancer deaths. The incidence of uterine LMS is 0.36 per 100,000 woman-years [5]; most occur in women over 40 years of age, with incidence increasing rapidly after age 50 [9]. Black women have a 2-fold higher incidence than white women. LMS may be associated with obesity and diabetes [6]. Tamoxifen use for N5 years may also increase LMS risk to 17 per 100,000 woman-years [7]. Additionally, studies in soft tissue sarcoma have attributed an increased risk of LMS with p53 gene mutations, radiation treatment for childhood cancers, and germ line mutations in fumarate hydratase (hereditary leiomyomatosis with renal cell carcinoma) [4]. Most uterine LMS is unassociated with preexisting leiomyomas and no biologic evidence exists to link LMS with their benign, smooth muscle uterine tumors. <ref name="ToroTravis2006">{{cite journal|last1=Toro|first1=Jorge R.|last2=Travis|first2=Lois B.|last3=Wu|first3=Hongyu Julian|last4=Zhu|first4=Kangmin|last5=Fletcher|first5=Christopher D.M.|last6=Devesa|first6=Susan S.|title=Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases|journal=International Journal of Cancer|volume=119|issue=12|year=2006|pages=2922–2930|issn=00207136|doi=10.1002/ijc.22239}}</ref>


=== Prevalence: ===
About 1 person in 100,000 gets diagnosed with LMS each year
=== Incidence: ===
Uterine sarcoma are extremely rare, with the incidence of 0.36 patients per 100,000 woman-years.<ref name="ToroTravis2006">{{cite journal|last1=Toro|first1=Jorge R.|last2=Travis|first2=Lois B.|last3=Wu|first3=Hongyu Julian|last4=Zhu|first4=Kangmin|last5=Fletcher|first5=Christopher D.M.|last6=Devesa|first6=Susan S.|title=Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases|journal=International Journal of Cancer|volume=119|issue=12|year=2006|pages=2922–2930|issn=00207136|doi=10.1002/ijc.22239}}</ref>
Uterine sarcoma are extremely rare, with the incidence of 0.36 patients per 100,000 woman-years.<ref name="ToroTravis2006">{{cite journal|last1=Toro|first1=Jorge R.|last2=Travis|first2=Lois B.|last3=Wu|first3=Hongyu Julian|last4=Zhu|first4=Kangmin|last5=Fletcher|first5=Christopher D.M.|last6=Devesa|first6=Susan S.|title=Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases|journal=International Journal of Cancer|volume=119|issue=12|year=2006|pages=2922–2930|issn=00207136|doi=10.1002/ijc.22239}}</ref>
 
Black women have a 2-fold higher incidence of development of the uterine Leiomyosarcoma as compared to the white women.  
=== Gender and Race: ===
Black women have a higher incidence of development of the uterine Leiomyosarcoma as compared to the white women.


==References==
==References==

Revision as of 14:26, 28 February 2019

Overview:

Leiomyosarcoma is one the most common types of soft tissue sarcoma.


Leiomyosarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Leiomyosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Leiomyosarcoma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Leiomyosarcoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Leiomyosarcoma epidemiology and demographics

CDC on Leiomyosarcoma epidemiology and demographics

Leiomyosarcoma epidemiology and demographics in the news

Blogs on Leiomyosarcoma epidemiology and demographics

Directions to Hospitals Treating Leiomyosarcoma

Risk calculators and risk factors for Leiomyosarcoma epidemiology and demographics

Epidemiology and demographics

Leiomyosarcoma is a rare tumor subtype, accounts for 1% of all uterine malignancies, but contributes to a significant proportion of uterine cancer deaths. The incidence of uterine LMS is 0.36 per 100,000 woman-years [5]; most occur in women over 40 years of age, with incidence increasing rapidly after age 50 [9]. Black women have a 2-fold higher incidence than white women. LMS may be associated with obesity and diabetes [6]. Tamoxifen use for N5 years may also increase LMS risk to 17 per 100,000 woman-years [7]. Additionally, studies in soft tissue sarcoma have attributed an increased risk of LMS with p53 gene mutations, radiation treatment for childhood cancers, and germ line mutations in fumarate hydratase (hereditary leiomyomatosis with renal cell carcinoma) [4]. Most uterine LMS is unassociated with preexisting leiomyomas and no biologic evidence exists to link LMS with their benign, smooth muscle uterine tumors. [1]

Uterine sarcoma are extremely rare, with the incidence of 0.36 patients per 100,000 woman-years.[1] Black women have a 2-fold higher incidence of development of the uterine Leiomyosarcoma as compared to the white women.

References

  1. 1.0 1.1 Toro, Jorge R.; Travis, Lois B.; Wu, Hongyu Julian; Zhu, Kangmin; Fletcher, Christopher D.M.; Devesa, Susan S. (2006). "Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases". International Journal of Cancer. 119 (12): 2922–2930. doi:10.1002/ijc.22239. ISSN 0020-7136.


Template:WikiDoc Sources